Vanguard Group’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.03B | Sell |
4,176,016
-242,594
| -5% | -$113M | 0.03% | 481 |
|
|
2025
Q3 | $1.85B | Sell |
4,418,610
-30,238
| -0.7% | -$10.2M | 0.03% | 499 |
|
|
2025
Q2 | $1.28B | Sell |
4,448,848
-8,287
| -0.2% | -$2.48M | 0.02% | 588 |
|
|
2025
Q1 | $1.37B | Buy |
4,457,135
+15,312
| +0.3% | +$5.25M | 0.02% | 553 |
|
|
2024
Q4 | $1.57B | Buy |
4,441,823
+32,213
| +0.7% | +$11.8M | 0.03% | 530 |
|
|
2024
Q3 | $1.58B | Sell |
4,409,610
-9,353
| -0.2% | -$3.16M | 0.03% | 538 |
|
|
2024
Q2 | $1.41B | Sell |
4,418,963
-264,132
| -6% | -$69.9M | 0.03% | 539 |
|
|
2024
Q1 | $1.08B | Buy |
4,683,095
+9,417
| +0.2% | +$2.13M | 0.02% | 630 |
|
|
2023
Q4 | $1.03B | Buy |
4,673,678
+10,767
| +0.2% | +$2.48M | 0.02% | 613 |
|
|
2023
Q3 | $1.05B | Buy |
4,662,911
+20,373
| +0.4% | +$4.69M | 0.03% | 584 |
|
|
2023
Q2 | $1.02B | Buy |
4,642,538
+36,621
| +0.8% | +$8.11M | 0.02% | 601 |
|
|
2023
Q1 | $1.03B | Buy |
4,605,917
+125,198
| +3% | +$30.9M | 0.03% | 584 |
|
|
2022
Q4 | $1.25B | Buy |
4,480,719
+69,103
| +2% | +$17.4M | 0.03% | 511 |
|
|
2022
Q3 | $924M | Buy |
4,411,616
+163,542
| +4% | +$36.6M | 0.03% | 592 |
|
|
2022
Q2 | $1B | Buy |
4,248,074
+79,278
| +2% | +$16.1M | 0.03% | 573 |
|
|
2022
Q1 | $748M | Buy |
4,168,796
+7,833
| +0.2% | +$1.49M | 0.02% | 735 |
|
|
2021
Q4 | $899M | Buy |
4,160,963
+695
| +0% | +$136K | 0.02% | 700 |
|
|
2021
Q3 | $768M | Sell |
4,160,268
-39,473
| -0.9% | -$7.78M | 0.02% | 751 |
|
|
2021
Q2 | $753M | Buy |
4,199,741
+92,535
| +2% | +$17.6M | 0.02% | 775 |
|
|
2021
Q1 | $687M | Buy |
4,107,206
+143,205
| +4% | +$23.9M | 0.02% | 777 |
|
|
2020
Q4 | $602M | Buy |
3,964,001
+80,132
| +2% | +$10.5M | 0.02% | 786 |
|
|
2020
Q3 | $392M | Sell |
3,883,869
-147,943
| -4% | -$16.2M | 0.01% | 880 |
|
|
2020
Q2 | $488M | Sell |
4,031,812
-111,830
| -3% | -$12.6M | 0.02% | 776 |
|
|
2020
Q1 | $393M | Buy |
4,143,642
+91,595
| +2% | +$8.71M | 0.02% | 777 |
|
|
2019
Q4 | $357M | Buy |
4,052,047
+150,659
| +4% | +$13.3M | 0.01% | 1013 |
|
|
2019
Q3 | $311M | Sell |
3,901,388
-87,127
| -2% | -$7.02M | 0.01% | 1056 |
|
|
2019
Q2 | $311M | Buy |
3,988,515
+33,194
| +0.8% | +$3.1M | 0.01% | 1077 |
|
|
2019
Q1 | $464M | Buy |
3,955,321
+48,042
| +1% | +$5.6M | 0.02% | 824 |
|
|
2018
Q4 | $426M | Buy |
3,907,279
+132,176
| +4% | +$15.3M | 0.02% | 785 |
|
|
2018
Q3 | $483M | Buy |
3,775,103
+61,361
| +2% | +$7.59M | 0.02% | 816 |
|
|
2018
Q2 | $420M | Buy |
3,713,742
+112,614
| +3% | +$12.4M | 0.02% | 866 |
|
|
2018
Q1 | $405M | Buy |
3,601,128
+60,551
| +2% | +$7.69M | 0.02% | 854 |
|
|
2017
Q4 | $524M | Buy |
3,540,577
+2,192
| +0.1% | +$279K | 0.02% | 729 |
|
|
2017
Q3 | $415M | Sell |
3,538,385
-271,761
| -7% | -$34.7M | 0.02% | 805 |
|
|
2017
Q2 | $494M | Buy |
3,810,146
+25,047
| +0.7% | +$3.12M | 0.02% | 709 |
|
|
2017
Q1 | $512M | Buy |
3,785,099
+256,514
| +7% | +$38.9M | 0.03% | 684 |
|
|
2016
Q4 | $506M | Sell |
3,528,585
-65,596
| -2% | -$8.37M | 0.03% | 649 |
|
|
2016
Q3 | $424M | Sell |
3,594,181
-37,821
| -1% | -$4.54M | 0.02% | 688 |
|
|
2016
Q2 | $385M | Buy |
3,632,002
+67,618
| +2% | +$7.54M | 0.02% | 707 |
|
|
2016
Q1 | $397M | Buy |
3,564,384
+206,833
| +6% | +$26.2M | 0.03% | 680 |
|
|
2015
Q4 | $526M | Buy |
3,357,551
+217,188
| +7% | +$31.6M | 0.04% | 557 |
|
|
2015
Q3 | $412M | Sell |
3,140,363
-36,155
| -1% | -$5.8M | 0.03% | 638 |
|
|
2015
Q2 | $553M | Buy |
3,176,518
+15,135
| +0.5% | +$2.72M | 0.04% | 551 |
|
|
2015
Q1 | $545M | Buy |
3,161,383
+150,453
| +5% | +$22.9M | 0.04% | 561 |
|
|
2014
Q4 | $390M | Buy |
3,010,930
+46,864
| +2% | +$6.04M | 0.03% | 647 |
|
|
2014
Q3 | $381M | Buy |
2,964,066
+135,013
| +5% | +$13.9M | 0.03% | 623 |
|
|
2014
Q2 | $250M | Sell |
2,829,053
-154,357
| -5% | -$14.8M | 0.02% | 846 |
|
|
2014
Q1 | $281M | Buy |
2,983,410
+98,296
| +3% | +$10.1M | 0.02% | 752 |
|
|
2013
Q4 | $326M | Buy |
2,885,114
+133,060
| +5% | +$12M | 0.03% | 638 |
|
|
2013
Q3 | $217M | Buy |
2,752,054
+112,866
| +4% | +$8.25M | 0.02% | 797 |
|
|
2013
Q2 | $174M | Buy |
+2,639,188
| New | +$170M | 0.02% | 840 |
|
Other funds holding UTHR
ACA
Vanguard Group's UTHR Position: Q4 2025 in Review
Vanguard Group reduced its United Therapeutics (UTHR) stake by 5.5% in Q4 2025, selling an estimated $113M and leaving 4,176,016 shares worth $2.03B. The position accounts for 0.03% of the portfolio, ranked #481.
Vanguard Group first reported a position in UTHR in Q2 2013 and has held it in 51 quarters since. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.
- Vanguard Group held 4,176,016 shares of United Therapeutics worth $2.03B as of Q4 2025.
- Vanguard Group sold 242,594 United Therapeutics shares in Q4 2025, an estimated $113M.
- United Therapeutics made up 0.03% of Vanguard Group's portfolio in Q4 2025, its #481 holding.
- Vanguard Group first reported a position in United Therapeutics in Q2 2013 and has held it in 51 quarters since.
- 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.